This study aims to learn about a medicine called nirmatrelvir/ritonavir for treating COVID-19 in kids under 18 who are not in the hospital but could get very sick. Researchers want to see how safe it is, how the body processes it, and how well it works. To join, kids must have tested positive for COVID-19 in the last 72 hours and started showing symptoms within the last 5 days. They cannot have been hospitalized for COVID-19, have certain serious health issues, or be on some other medications.
- The study focuses on kids under 18 with COVID-19 who are at risk of severe disease.
- The medicine's safety and effectiveness are being tested.
- Participants should not have been hospitalized for COVID-19 or have specific health conditions.